Results 231 to 240 of about 27,194 (296)

Clinical Spectrum and Outcomes of SOX1 Antibody‐Associated Paraneoplastic Neurological Syndromes: A Chinese Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background SOX1 antibody‐positive paraneoplastic neurological syndromes (PNS) exhibit significant population‐specific clinical heterogeneity. While Western cohorts predominantly manifest Lambert‐Eaton myasthenic syndrome (65%–80%), comprehensive clinical characterization and treatment response data in Asian populations remain critically ...
Jin‐Long Ye, Zu‐Ying Kuang, Bo Li, Meng‐Qiu Pan, Li‐Hua Zhou, Yang‐Yang Dai, Si‐Fen Xie, Xian‐Guang Lin, Ye‐Peng Hu, Li‐Hong Jiang, Zhan‐Hang Wang, Wei‐Jing Zhang   +11 more
wiley   +1 more source

Clustering Algorithm Reveals Dopamine‐Motor Mismatch in Cognitively Preserved Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the relationship between dopaminergic denervation and motor impairment in two de novo Parkinson's disease (PD) cohorts. Methods n = 249 PD patients from Parkinson's Progression Markers Initiative (PPMI) and n = 84 from an external clinical cohort.
Rachele Malito, Chiara Meneghini, Alice Galli, Luca Gallo, Pierfrancesco Mitrotti, Paola Dimartino, Marianna Inglese, Cinzia Zatti, Alessandro Lupini, Andrea Pilotto, Alessandro Padovani, Micol Avenali, Enza Maria Valente, Cristina Tassorelli, Silvia P. Caminiti   +14 more
wiley   +1 more source

Use of design thinking to develop a benchmarking tool to assess documentation procedures in a hospital pharmacy aseptic compounding unit: a case study. [PDF]

Eur J Hosp Pharm
Murphy N, Garvey E, Naughton BD.
europepmc   +1 more source

Value of MRI Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To examine the value of MRI outcomes as endpoints for preventive and early‐stage trials of two polyglutamine spinocerebellar ataxias (SCAs). Methods A cohort of 100 participants (23 SCA1, 63 SCA3, median Scale for the Assessment and Rating of Ataxia (SARA) score = 5, 42% preataxic, and 14 gene‐negative controls) was scanned at 3T up ...
Thiago J. R. Rezende, Emilien Petit, Young Woo Park, Sophie Tezenas du Montcel, James M. Joers, Jonathan M. DuBois, H. Moore Arnold, Michal Povazan, Ipek Özdemir, Guita Banan, Romain Valabregue, Philipp Ehses, Jennifer Faber, Chiadi U. Onyike, Peter B. Barker, Jeremy D. Schmahmann, Eva‐Maria Ratai, Sub H. Subramony, Thomas H. Mareci, Khalaf O. Bushara, Henry Paulson, Thomas Klockgether, Alexandra Durr, Tetsuo Ashizawa, Christophe Lenglet, Gülin Öz, READISCA Investigators   +26 more
wiley   +1 more source

Guiding syringe selection for intravitreal injections: injectability and stability analysis of compounded pegcetacoplan (SYFOVRE) and the broader implications for high-viscosity ophthalmic therapies. [PDF]

Int J Retina Vitreous
Felfeli T, Lane NM, Mandelcorn ED.
europepmc   +1 more source

A Risk-Based Framework for Hospital Compounding: Integrating Degradation Mechanisms and Predictive Toxicology. [PDF]

Pharmaceutics
Secretan PH, Annereau M, Do B.
europepmc   +1 more source

Parenteral nutrition practice in the United States: A cross-sectional survey with gap analysis. [PDF]

JPEN J Parenter Enteral Nutr
Ayers P, Boullata JI, Canada TW, Cogle SV, Mays A, Monczka J, Owen-Michaane M, Afolabi TM, Biggs E, Petrea Cober M, Coscia E, Durfee SM, Figueiroa S, Hand RK, Roehl K, Stanner H, Price K.   +16 more
europepmc   +1 more source

Hospital-Compounded Birabresib Capsules for NUT Carcinoma: A Quality- and Risk-Based CMC Strategy. [PDF]

Pharm Res
Annereau M, Legrand FX, Sánchez-Becerra MV, Ramos S, Duperray F, Denis L, Sizun C, Durand S, Salomon V, Besse B, Do B.   +10 more
europepmc   +1 more source

Anti-VEGF safety in evolution: A comprehensive review of ocular and systemic considerations. [PDF]

Indian J Ophthalmol
Venkatesh R, Biradar P, Malwe G, Prabhu V, Hande P, Kathare R, Raj P, Roy R, Yadav NK, Jayadev C.   +9 more
europepmc   +1 more source